Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.45 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.41 |
| ▸ | ITGAL | P20701 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16819867 | 1.00 | CYP3A4 (0.48) | CYP3A4SLC7A5EPHX2SLC6A5QPCT | |
| SCHEMBL15426847 | 0.92 | QPCT (0.45) | CYP3A4SLC7A5EPHX2SLC6A5QPCT | |
| SCHEMBL16819869 | 0.92 | EPHX2 (0.45) | CYP3A4SLC7A5EPHX2SLC6A5QPCT | |
| SCHEMBL15412853 | 0.89 | EPHX2 (0.49) | CYP3A4SLC7A5EPHX2SLC6A5QPCT | |
| SCHEMBL20384898 | 0.89 | EPHX2 (0.49) | CYP3A4SLC7A5EPHX2SLC6A5QPCT | |
| SCHEMBL17866301 | 0.88 | SLC6A5 (0.49) | CYP3A4SLC7A5EPHX2SLC6A5QPCT | |
| SCHEMBL15413155 | 0.87 | PTGS1 (0.44) | CYP3A4SLC7A5EPHX2SLC6A5QPCT | |
| SCHEMBL15426863 | 0.87 | CYP3A4 (0.53) | CYP3A4SLC7A5EPHX2SLC6A5SLC15A2 | |
| SCHEMBL16819868 | 0.87 | CYP3A4 (0.53) | CYP3A4SLC7A5EPHX2SLC6A5SLC15A2 | |
| SCHEMBL16819871 | 0.86 | REN (0.45) | CYP3A4EPHX2SLC6A5QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028935-B2 | Stabilized multi-functional antioxidant compounds and methods of use | XPD HOLDINGS, LLC (US) | 2018-07-24 | — | — | US | claimed |
| US-20170135986-A1 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE | XPD HOLDINGS, LLC | 2017-05-18 | — | — | US | claimed |
| US-9382211-B2 | Stabilized multi-functional antioxidant compounds and methods of use | XPD HOLDINGS, LLC (US) | 2016-07-05 | — | — | US | claimed |
| US-20150175552-A1 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE | XPD HOLDINGS, LLC | 2015-06-25 | — | — | US | claimed |
| US-10028935-B2 | Stabilized multi-functional antioxidant compounds and methods of use | XPD HOLDINGS, LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028935-B2 | Stabilized multi-functional antioxidant compounds and methods of use | XPD HOLDINGS, LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170135986-A1 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE | XPD HOLDINGS, LLC | 2017-05-18 | — | — | US | disclosed |
| US-20170135986-A1 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE | XPD HOLDINGS, LLC | 2017-05-18 | — | — | US | disclosed |
| US-9593079-B2 | Stabilized multi-functional antioxidant compounds and methods of use | XPD HOLDINGS, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593079-B2 | Stabilized multi-functional antioxidant compounds and methods of use | XPD HOLDINGS, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-9382211-B2 | Stabilized multi-functional antioxidant compounds and methods of use | XPD HOLDINGS, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382211-B2 | Stabilized multi-functional antioxidant compounds and methods of use | XPD HOLDINGS, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160185718-A1 | Stabilized Multi-Functional Antioxidant Compounds and Methods of Use | XPD HOLDINGS, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160185718-A1 | Stabilized Multi-Functional Antioxidant Compounds and Methods of Use | XPD HOLDINGS, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20150175552-A1 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE | XPD HOLDINGS, LLC | 2015-06-25 | — | — | US | disclosed |
| US-20150175552-A1 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE | XPD HOLDINGS, LLC | 2015-06-25 | — | — | US | disclosed |
| WO-2014011624-A2 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE | XPD HOLDINGS LLC (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028935-B2 | Stabilized multi-functional antioxidant compounds and methods of use | SOD1, GPX4, SOD3 | CYP3A4 3558/4885SLC7A5 2745/4885EPHX2 3420/4885 |
| US-20150175552-A1 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE | SOD1, GPX4, SOD3 | CYP3A4 3558/4885SLC7A5 2745/4885EPHX2 3420/4885 |
| US-20170135986-A1 | STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE | SOD1, GPX4, SOD3 | CYP3A4 3558/4885SLC7A5 2745/4885EPHX2 3420/4885 |
| US-20160185718-A1 | Stabilized Multi-Functional Antioxidant Compounds and Methods of Use | SOD1, GPX4, SOD3 | CYP3A4 3558/4885SLC7A5 2745/4885EPHX2 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.